Drug Profile
Research programme: torsin A activators - QRxPharma/University of Alabama
Alternative Names: T9001Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator University of Alabama
- Developer QRxPharma; University of Alabama
- Class Small molecules
- Mechanism of Action Molecular chaperone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Dystonia; Parkinson's disease
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Dystonia in USA (unspecified route)
- 23 Feb 2023 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Dystonia in USA